Background. Guillain-Barre syndrome is an immune-mediated polyradiculoneuropathy characterized by acute neurological symptoms, usually following an infectious disease. The discovery of links between coronavirus infection and GBS has made the analysis even more relevant. The aim. To evaluate the efficacy of rehabilitation for patients with GuillainBarre syndrome (GBS). Methods. A systematic literature review was performed according to PRISMA statement. A literature search had begun on January 10, 2022, and ended on May 1, 2022. The search was performed in Pubmed, ScienceDirect, and ClinicalKey databases. Inclusion criteria were research articles published less than five years ago, written in English, evaluating the efficacy of rehabilitation for patients with GBS. Results. The research strategy identified 606 results. After excluding duplicates (n = 230), and after a thorough assessment, six studies were included. Every study showed positive effects of rehabilitation in patients with GBS. Two studies used GBS – Disability Score to evaluate rehabilitation efficacy, which had positive results (p < 0.0001 and p < 0.01). Another study found that supervised, individualized exercise was more efficient than unsupervised home exercise. There was also a study with groups of children with GBS, who had electromyographic biofeedback therapy, that showed positive dynamics (p < 0.05). Another study assessed neuropathic pain and presented a reduction in pain after rehabilitation (p < 0.05). Conclusion. Patients with GBS have achieved significant positive changes in mobility, cognitive function, and performance of daily tasks after rehabilitation treatment. Keywords: Guillain-Barre syndrome, rehabilitation, electrical stimulation, physical therapy, exercise.

Autoimmune processes are an increasingly recognized cause of seizures. Antibodies against neuronal surface antigens are implicated in the development of acute symptomatic seizures secondary to autoimmune encephalitis, whereas antibodies against intracellular antigens (anti-glutamic acid decarboxylase (GAD) and onconeural antibodies) are found in cases of autoimmune-associated epilepsy (AAE). AAE is described as isolated drug-resistant epilepsy without any specific magnetic resonance imaging (MRI) or cerebrospinal fluid changes and with a very limited response to immunotherapy. We present a clinical case and a literature review on autoimmune-associated epilepsy to increase awareness of this disease and illustrate its complexity. This is a clinical case of a female with a history of refractory focal epilepsy. The patient had been given several trials of multiple antiepileptic drugs and their combinations without any clear effect. Multiple evaluations including brain MRI, PET, and interictal and ictal electroencephalograms were performed. An APE2 score was calculated with a result of 4 and, in the presence of anti-GAD65 antibodies in the serum, the diagnosis of AAE was confirmed. There was no effect after five sessions of plasma exchange; however, after a course of intravenous immunoglobulin, a positive but temporary clinical effect was noticed: anti-GAD65 levels initially decreased but rebounded to previous levels 6 months later.